GlassScriptPhysician profile
Tammy S Mackiewicz
NPI 1790054252
$11,434.76
in general payments reported to CMS, 2019-2025
58 companies · $2,407 in 2025
The $2,407 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,292 · 2022: $2,408 · 2023: $2,701 · 2024: $2,627 · 2025: $2,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,657 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,656.75 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,060.68 | 2021-2025 | |
| Lilly USA, LLC | $705.29 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $680.61 | 2021-2025 | Darzalex, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $622.27 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $596.11 | 2021-2025 | Enhertu, Lynparza, Imfinzi |
| Pfizer INC. | $586.54 | 2021-2025 | |
| Incyte Corporation | $551.73 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $536.99 | 2021-2025 | Vyloy, Xtandi, Padcev |
| Gilead Sciences, INC. | $507.21 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $441.34 | 2021-2025 | |
| Daiichi Sankyo INC. | $406.12 | 2021-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $387.18 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $338.69 | 2021-2025 | Opdivo, Krazati, Augtyro |
| Seagen INC. | $325.66 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Regeneron Healthcare Solutions, INC. | $312.55 | 2023-2025 | Libtayo |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $264.64 | 2022-2025 | Reblozyl |
| Abbvie INC. | $261.36 | 2024-2025 | |
| Array Biopharma INC | $231.87 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $177.16 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.69 | 2021-2024 | Alunbrig, Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $167.18 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| Amgen INC. | $124.20 | 2021-2023 | Blincyto, Kyprolis, Lumakras |
| Genentech USA, INC. | $120.76 | 2022-2023 | Perjeta, Kadcyla, Phesgo |
| Kite Pharma, INC. | $111.64 | 2023-2025 | Yescarta |
| Eisai INC. | $102.19 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $99.79 | 2021-2024 | Ultomiris |
| Emd Serono, INC. | $98.26 | 2021-2025 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $95.04 | 2022-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $86.82 | 2021-2024 | |
| Pharmaessentia USA Corporation | $81.99 | 2023-2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $76.98 | 2021-2025 | Fotivda |
| Sobi, INC | $72.94 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.72 | 2021-2023 | Gilotrif |
| Taiho Oncology, INC. | $65.32 | 2023-2025 | |
| Blueprint Medicines Corporation | $63.60 | 2022-2024 | Ayvakit |
| Stemline Therapeutics INC. | $62.93 | 2023-2025 | Orserdu |
| Legend Biotech USA INC. | $62.36 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $58.05 | 2023-2024 | Cosela, Monoferric |
| Cti Biopharma Corp. | $54.27 | 2022-2023 | Vonjo |
| Mirati Therapeutics, INC. | $51.78 | 2023 | Krazati |
| G1 Therapeutics, INC. | $51.59 | 2022-2023 | Cosela |
| Deciphera Pharmaceuticals INC. | $44.96 | 2021-2023 | Qinlock |
| Kyowa Kirin, INC. | $41.60 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $41.54 | 2023-2024 | Xpovio |
| Ge Healthcare | $40.09 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $36.53 | 2023-2024 | Onivyde, Somatuline Depot |
| Servier Pharmaceuticals LLC | $33.93 | 2021 | |
| Apellis Pharmaceuticals, INC. | $31.48 | 2023 | Empaveli |
| Rigel Pharmaceuticals, INC. | $30.64 | 2022-2023 | Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $29.57 | 2021-2023 | Xarelto |
| Beone Medicines USA, INC. | $27.14 | 2025 | Tevimbra |
| Sumitomo Pharma America, INC. | $23.46 | 2023 | Orgovyx |
| Agios Pharmaceuticals, INC. | $20.52 | 2021 | |
| Morphosys, US INC. | $19.50 | 2023 | Monjuvi |
| Amag Pharmaceuticals, INC. | $18.06 | 2022 | |
| Recordati_rare_diseases_inc. | $17.25 | 2025 | Enjaymo |
| Myovant Sciences INC. | $14.84 | 2022 | |
| Dova Pharmaceuticals | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Mackiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.